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Skin reactions-RTOG(4).
Incidence of moist desquamation in the inframammary fold.
Dose to OAR (mean lung and mean heart doses).
Patient comfort.
Patient modesty (5).
Patient empowerment(6)
Acceptance using an adapted technology acceptance tool(7).
Body Image(8)
The following measures were included:
This study showed that mean ipsilateral lung dose was lower for women treated 
with the S4A bra. Mean heart dose was no different. Differences in systematic and 
random errors were not clinically significant. Skin reactions indicated no clinically 
detectable adverse effect of the bra material, and no serious adverse events were 
reported. There was improved modesty and dignity, and improved empowerment, 
(higher mean empowerment questionnaire scores) in the S4A bra arm. 
This was a feasibility trial and a larger multi-centre study is now needed.
For further information please contact: 
Professor Heidi Probst  -  h.probst@shu.ac.uk
Conclusion:
Improvements in cancer specific and overall survival 
for women with early breast cancer have led to more 
focus on the long-term toxicities of treatment. Whole 
breast radiotherapy has been shown to increase the risk 
of developing ischaemic heart disease(1), symptomatic 
pulmonary fibrosis or a second primary cancer of the lung 
(2, 3). Hence it is important to investigate methods to reduce 
radiation doses to these critical OAR. We have developed a 
novel support bra (S4A bra) to lift the breast away from the 
chest wall, particularly suited for women with larger breast size.
Background:
The primary purpose of this trial was to test the feasibility of using 
the S4A bra for women undergoing breast irradiation (following a 
wide local excision) and to determine acceptability of the pathway 
to patients and clinicians. Feasibility and efficacy endpoints were 
measured to inform the design of a future larger randomised 
controlled trial and to confirm safety of the device.
Purpose:
This was a single centre randomised feasibility trial. Eligible patients were 
assigned to either the S4A bra (group A) or standard positioning without 
immobilisation (group B) via a computer-generated randomisation process 
that was remote to the clinical and S4A project team; randomisation was 
stratified by breast size. All patients received 40Gy in 15 fractions over 3 
weeks without a boost and without regional nodal irradiation; 
no bolus was applied to any patients.
 
Patients in the intervention arm received two planning CT scans 
(using a repeated measure design); one CT scan while wearing 
the S4A bra and one scan without the bra, to enable 
a direct comparison of OAR doses. Data on 
set up reproducibility were measured using 
2D on treatment images (5 images per 
patient).
Method:
Results:
The Consort diagram in Figure 1 shows recruitment and allocation. 
Population systematic errors for central lung depth was 0.9mm for the S4A 
arm and -1.5mm for the control (difference 2.4mm CI 0.9-3.9). There was a 
difference in systematic error in the cranial-caudal distance (CCD) 2.7mm (S4A 
bra) vs 1.5mm. Differences in random errors between the groups were all below 
1mm except for CCD where there was a small difference in favour of the control 
arm (2.4mm difference). RTOG scores were comparable between the groups and 
no grade 3 reactions were reported in either arm. No difference in mean heart 
dose was identified (mean heart doses were all <1.5Gy) patients treated for a 
left breast cancer had DIBH irrespective of treatment arm. Table 1 shows an 
improvement in mean ipsilateral lung dose when using the S4A bra in both right 
and left sided cases (mean improvement 1.13Gy, and 0.391Gy respectively).
Heidi Probst1, Heath Reed1, Andrew Stanton1, Clare Robertson2, 
Rebecca Simpson3, Stephen Walters3, Helen Simpson4, 
Gillian Brown4, Sarah Hielscher4, Kirsty Bryan-Jones4, 
Janet Johnson4, Janet Horsman3, Omar Din4
1.  Darby  SC, Ewertz  M, McGale  P, Bennet  AM, Blom-Goldman  U, Brøn-
num  D, et al. Risk of Ischemic Heart Disease in Women after Radiotherapy 
for Breast Cancer. New England Journal of Medicine. 2013;368(11):987-98.
2.  Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the Risks 
of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and 
Heart and From Previous Randomized Trials. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2017;35(15):1641-9.
3.  Grantzau T, Thomsen MS, Vaeth M, Overgaard J. Risk of second primary 
lung cancer in women after radiotherapy for breast cancer. Radiotherapy and 
oncology : journal of the European Society for Therapeutic Radiology and 
Oncology. 2014;111(3):366-73.
1. 2. 3. 4.
Allocation
A No Bra Right 4.851 2.636 10
A With Bra Right 3.720 2.017 10
A No Bra Left 3.622 1.704 13
A With Bra Left 3.231 1.539 13
With or
Without Bra
Side
Treated
Ipsilateral
mean (Gy)
Combined
lungs mean (Gy)
Number
(n=)
Enrolment Assessed for eligibility (n=94)
Randomised n=50
Discontinued intervention n=0 Discontinued intervention n=0
Excluded n=44
Not meeting inclusion criteria n=21
Declined to participate n=22
Other reasons n=1
Allocated to control (standard care no 
immobilisation) n=25
    Received Standard Control n=25
     Did not receive intervention n=0
Analysed
Within subjects planning analysis n=23
Treatment data available for analysis n=18
Excluded from analysis n=0
Analysed n=25
Excluded from analysis n=0
Allocated to intervention n=25
Received intervention n=18
Did not receive intervention n=7
   Plan rejected by Clinician n=4
    Clinician rejected before planning n=1
    Unable to fit bra due to breast size  
    differences of each side n=1
    Unable to avoid contralateral breast with 
    medial field n=1
Figure 1 Consort Diagram:
Allocation
Follow up
Analysis
